Next Article in Journal
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN™ for Improving Sleep
Next Article in Special Issue
Potentially Inappropriate Medications Involved in Drug–Drug Interactions in a Polish Population over 80 Years Old: An Observational, Cross-Sectional Study
Previous Article in Journal
High-Altitude Medicinal Plants as Promising Source of Phytochemical Antioxidants to Combat Lifestyle-Associated Oxidative Stress-Induced Disorders
Previous Article in Special Issue
Advances in Nanomedicine for Precision Insulin Delivery
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 17
Issue 8
10.3390/ph17080976
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Autoimmune Thyroiditis Mitigates the Effect of Metformin on Plasma Prolactin Concentration in Men with Drug-Induced Hyperprolactinemia

by
Robert Krysiak
*,
Marcin Basiak
,
Witold Szkróbka
and
Bogusław Okopień
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2024, 17(8), 976; https://doi.org/10.3390/ph17080976
Submission received: 26 June 2024 / Revised: 16 July 2024 / Accepted: 18 July 2024 / Published: 23 July 2024
(This article belongs to the Special Issue Advancements in Cardiovascular and Antidiabetic Drug Therapy)
Browse Figure
Versions Notes

Abstract

:
Metformin inhibits the secretory function of overactive anterior pituitary cells, including lactotropes. In women of childbearing age, this effect was absent if they had coexisting autoimmune (Hashimoto) thyroiditis. The current study was aimed at investigating whether autoimmune thyroiditis modulates the impact of metformin on the plasma prolactin concentration in men. This prospective cohort study included two groups of middle-aged or elderly men with drug-induced hyperprolactinemia, namely subjects with concomitant Hashimoto thyroiditis (group A) and subjects with normal thyroid function (group B), who were matched for baseline prolactin concentration and insulin sensitivity. Titers of thyroid peroxidase and thyroglobulin antibodies, levels of C-reactive protein, markers of glucose homeostasis, concentrations of pituitary hormones (prolactin, thyrotropin, gonadotropins, and adrenocorticotropic hormone), free thyroxine, free triiodothyronine, testosterone, and insulin growth factor-1 were measured before and six months after treatment with metformin. Both study groups differed in titers of both antibodies and concentrations of C-reactive protein. The drug reduced the total and monomeric prolactin concentration only in group B, and the impact on prolactin correlated with the improvement in insulin sensitivity and systemic inflammation. There were no differences between the follow-up and baseline levels of the remaining hormones. The results allow us to conclude that autoimmune thyroiditis mitigates the impact of metformin on prolactin secretion in men.

1. Introduction

Despite maintaining anatomical and functional connections with the brain, the pituitary is situated outside the blood–brain barrier [1]. This fact may explain why metformin, a drug of unquestionable importance in the treatment of type-2 diabetes and other insulin-resistant states [2], preferentially accumulates in this structure [3] and attenuates the secretory function of different anterior pituitary cells, including thyrotropes [4,5], gonadotropes [6,7], and lactotropes [8,9,10,11,12]. Interestingly, and probably importantly from the clinical point of view, the inhibitory effect on thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin in these studies was observed only if their baseline levels were elevated. There is no evidence that metformin administration, even at high doses, results in a deficiency of pituitary hormones. The decrease in prolactin secretion has been reported irrespective of the reason for prolactin excess, including in subjects with prolactinomas [8], empty sella syndrome [8], traumatic brain injury [8], drug-induced hyperprolactinemia [9,10,11,12], and in hyperprolactinemia of unknown origin [8]. Unlike most cases of prolactin excess, which may be effectively treated with dopamine agonists (mainly bromocriptine and cabergoline), the use of these agents in antipsychotics-induced hyperprolactinemia is much more controversial because they may aggravate psychiatric disability [13]. Considering doubts concerning the use of dopaminergic agents and the functional basis of this disorder, metformin is regarded by some research groups as a potential, emerging treatment for drug-induced prolactin excess [14]. It should be kept in mind that even moderate long-term prolactin excess, irrespective of gender, predisposes to insulin resistance, prediabetes, atherogenic dyslipidemia, excessive and/or subnormal fat accumulation, subclinical atherosclerosis, and endothelial dysfunction [15,16,17,18,19,20], and therefore, it should be avoided. It seems that metformin is characterized by differences in the action of lactotrope function in different populations of subjects with hyperprolactinemia. The impact of this agent on circulating prolactin levels was found to be determined by sex because in young adults the drug reduced prolactin levels only in women but not in men [21]. Moreover, metformin reduces prolactin levels in men if they have low, but not if they have normal, testosterone concentrations [22]. These discrepancies suggest that the impact of metformin on prolactin secretion may be more prominent in individuals with low testosterone production. Testosterone deficiency may make patients with prolactin excess particularly prone to cardiometabolic complications because low testosterone production in men is often associated with metabolic comorbidities, such as obesity, insulin resistance, metabolic syndrome, and type-2 diabetes mellitus [23,24].
Recently, our research team reported that coexisting autoimmune (Hashimoto) thyroiditis mitigated the impact of metformin on the secretory function of the anterior pituitary cells of women, including attenuation of the prolactin-lowering effect [25,26]. This finding seems to be clinically relevant because Hashimoto thyroiditis is one of the most common human disorders and the most prevalent organ-specific autoimmune disorder worldwide [27,28]. Despite the female preponderance of autoimmune thyroiditis, more and more males are being diagnosed with this clinical entity [29]. To the best of our knowledge, no previous study investigated the association between metformin and autoimmune thyroiditis at the level of male lactotropes. Few studies conducted so far suggest that low testosterone concentrations and autoimmune thyroiditis are, in men, reciprocally related. Males with primary hypothyroidism, caused in the majority of patients by autoimmune thyroid disease, were characterized by gonadal hypofunction [30]. A higher ratio of estradiol to testosterone in males was associated with autoimmune thyroid disease [31]. Shorter AR (CAG)n repeats, increasing the activity of the androgen receptor, were found to predispose to a younger onset of autoimmune thyroid disease [32]. Moreover, Hashimoto thyroiditis is highly prevalent in individuals with Klinefelter’s syndrome, the most prevalent sex-chromosome disorder resulting in male hypogonadism [33]. Lastly, exogenous testosterone reduced thyroid antibody titers in euthyroid men with testosterone deficiency and Hashimoto thyroiditis [34]. In addition to the association with testosterone deficiency, particularly in individuals with markedly elevated prolactin levels [35]; increased prolactin production may predispose to the development and progression of autoimmune disorders, including autoimmune thyroiditis [36]. Thus, the present study investigated whether coexisting euthyroid Hashimoto thyroiditis modulates the impact of chronic metformin treatment on plasma prolactin levels in middle-aged and elderly men with antipsychotic-induced hyperprolactinemia.

2. Results

The study groups were comparable with respect to age, smoking, percentages of patients with type-2 diabetes and prediabetes, BMI, and blood pressure (systolic and diastolic) (Table 1). Titers of thyroid antibodies (both TPOAb and TgAb, and the concentration of hsCRP were higher in group A than in group B. Levels of glucose, glycated hemoglobin, pituitary hormones (prolactin [total and monomeric], TSH, FSH, LH and ACTH, macroprolactin), free thyroid hormones, testosterone, IGF-1, and HOMA-IR, did not differ between groups A and B (Table 2).
Metformin treatment was well tolerated; side effects (decreased appetite, transient diarrhea, tiredness, and weakness) were mild and present only in the minority of patients (12.5% in group A and 8.3% in group B). Because no patient prematurely discontinued the treatment, the data of all included individuals were statistically analyzed. Over the entire study period, all patients adhered to the treatment recommendations and the recommendations concerning diet and physical activity.
Metformin did not affect BMI (group A: 24.9 ± 4.3 kg/m2 vs. 24.3 ± 4.6 kg/m2 [p = 0.6428], group B: 24.5 ± 4.8 kg/m2 vs. 23.9 ± 4.1 kg/m2 [p = 0.6437]), and follow-up BMI did not differ between both groups (p = 0.7519). In both treatment groups, metformin decreased glucose, HOMA-IR, and glycated hemoglobin. In group B, but not in group A, there were differences between the baseline and the follow-up plasma concentrations of both total and monomeric prolactin and in hsCRP. Titers of TPOAb and TgAb, concentrations of macroprolactin, TSH, free thyroxine, free triiodothyronine, gonadotropins, testosterone, ACTH, and IGF-1 remained at similar levels over the entire study period. At the end of the study, there were between-group differences in glucose, HOMA-IR, glycated hemoglobin, total prolactin, monomeric prolactin, antibody titers, and hsCRP (Table 2).
The study groups differed in the percent changes from baseline for glucose, HOMA-IR, glycated hemoglobin, total prolactin, monomeric prolactin, testosterone, and hsCRP, which were greater in group B than in group A (Table 3).
At the beginning of the study, in group A, there were positive correlations between the hsCRP concentration and the antibody titers (TPOAb: r = 0.462, p = 0.0002; TgAb: r = 0.398, p = 0.0011). The effect of treatment on the total and monomeric prolactin correlated with the (a) baseline concentrations (total prolactin—group A: r = 0.411, p = 0.0008, group B: r = 0.325, p = 0.0322; monomeric prolactin—group A: r = 0.442, p = 0.0004, group B: r = 0.346, p = 0.0226), (b) the impact of treatment on HOMA-IR (total prolactin—group A: r = 0.368, p = 0.0282, group B: r = 0.340, p = 0.0226; monomeric prolactin—group A: r = 0.394, p = 0.0014, group B: r = 0.411, p = 0.0008), and (c) in group B additionally, also with treatment-induced reduction in hsCRP concentration (r = 0.365, p = 0.0122 for total prolactin; r = 0.385, p = 0.0043 for monomeric prolactin). In group A, there were inverse correlations between the baseline antibody titers and metformin action on total prolactin (r = −0.402, p = 0.0005 for TPOAb; r = −0.375, p = 0.0049 for TgAb) and on monomeric prolactin (r = −0.387, p = 0.0023 for TPOAb; r = −0.341, p = 0.0274 for TgAb), as well as between treatment-induced changes in HOMA-IR and the baseline hsCRP (r = −0.352, p = 0.0126). In group B, treatment-induced changes in prolactin correlated with the impact of treatment on LH (r = 0.315, p = 0.0312 for total prolactin; r = 0.342, p = 0.0265 for monomeric prolactin) and inversely with the baseline testosterone (r = −0.265, p = 0.0489 for total prolactin; r = −0.269, p = 0.0411 for monomeric prolactin). The remaining correlations were insignificant.

3. Discussion

The study showed a decrease in prolactin concentrations in men aged between 50 and 75 years with elevated levels of this hormone who do not have concurrent thyroid disease. This finding contrasts with our previous observations concerning a neutral effect of metformin on prolactin levels in a younger population of hyperprolactinemic men [21]. This incongruency may be well explained by lower mean testosterone concentrations in the participants of the current study. In line with this interpretation, the reduction in the prolactin concentration is inversely correlated with the plasma testosterone concentration. Another interesting finding is that the decrease in the total prolactin level reflected a reduction in the monomeric form of prolactin. In turn, the concentration of macroprolactin, high molecular mass forms of this hormone, composed of antigen–antibody complexes of prolactin and aggregates of covalent or noncovalent polymers of monomeric prolactin [37], remained unchanged, which has been evidenced so far only in women [38]. The obtained results indicate that metformin treatment should be considered in middle-aged elderly men with diabetes or prediabetes coexisting with an elevated prolactin concentration. Because of the cardiometabolic and bone consequences of long-term prolactin excess, the risk of which increases with age [39], metformin treatment seems to bring benefits even in men with asymptomatic hyperprolactinemia. Another argument in favor of metformin is that antipsychotics seem to increase the risk of developing diabetes [40], the presence of which additionally justifies this treatment. It is worth noting that metformin treatment was well tolerated by men receiving antipsychotic drugs and did not worsen the effectiveness of antipsychotic therapy.
Metformin treatment did not significantly affect gonadotropin levels, though both groups differed in the strength of the prolactin-lowering effect, and in men without thyroid pathology, the decrease in plasma prolactin positively correlated with the impact of treatment on LH. This finding may suggest that metformin exerted a weak, and statistically insignificant, inhibitory effect on gonadotropin secretion in this population. The study included men with only mild or moderate prolactin excess but not individuals with severe hyperprolactinemia, which is often complicated by gonadal failure [41]. Thus, a relatively low mean baseline testosterone concentration (though in the majority of patients still within the reference range) was probably a consequence of age-related changes in testosterone production (late-onset hypogonadism), while the association with prolactin excess was less convincing. This explains why the improvement in lactotrope function did not result in statistically significant changes in gonadotropins and testosterone.
Undoubtedly, a novel observation of our present study is that the impact on prolactin concentration was absent in men with concurrent euthyroid Hashimoto thyroiditis. Although autoimmune thyroiditis is the major cause of hypothyroidism in developed countries, less pronounced lymphocytic infiltration and fibrotic reactions do not result in thyroid hypofunction [42]. Consequently, euthyroid Hashimoto thyroiditis is considered a milder form of autoimmune thyroiditis than hypothyroid Hashimoto thyroiditis and often precedes the hypothyroid phase [43]. Because untreated or inadequately treated hypothyroidism often causes hyperprolactinemia [44], making it difficult to differentiate prolactin excess secondary to thyroid hypofunction and antipsychotic treatment, the study included only patients with normal concentrations of TSH, free thyroxine, and free triiodothyronine, which were suggestive of an intact hypothalamic–pituitary–thyroid axis activity. Another reason for including only euthyroid men is the link between schizophrenia and hypothyroidism resulting in that all patients receiving antipsychotics on a chronic basis should be effectively substituted with thyroid hormones [45]. Thus, our findings cannot be explained by thyroid hypofunction. Moreover, because of matching, they cannot be attributed to baseline differences in prolactin concentration and insulin sensitivity. Lastly, they cannot be explained by differences in testosterone production, which was similar in both study groups, as well as by other differences between the groups. Thus, attenuation of the prolactin-lowering effect of metformin was likely associated with thyroid autoimmunity. In line with this explanation, titers of TPOAb and TgAb, which determine the severity of Hashimoto thyroiditis [28], inversely correlated with the impact of metformin on total and monomeric prolactin. Our finding is consistent with similar observations in women [25,26], which suggest that the pituitary effects of metformin are mitigated by Hashimoto thyroiditis, irrespective of gender.
In the investigated population of middle-aged and elderly men, metformin did not affect thyroid antibody titers. This finding is in disagreement with the results of a meta-analysis of four clinical studies [46], which showed a reduction in both TPOAb and TgAb. There are different possible explanations for these contradictory results. They may be attributed to differences in the assessed populations because the meta-analysis by Jia et al. included mainly women of reproductive age (the percentage of men was very low). Second, a remarkable proportion of the analyzed patients was diagnosed with subclinical hypothyroidism. Thus, the degree of inflammation and the destruction of thyrocytes was greater than in the current study. Finally, we recruited a smaller number of patients in comparison with the number of individuals included in the mentioned Chinese meta-analysis. A neutral effect on thyroid antibody titers indicates that the weak effects of metformin on prolactin levels in patients with autoimmune thyroiditis cannot be explained by a direct involvement of these antibodies.
Another finding attracting attention is the positive correlations between the impact of treatment on prolactin and insulin sensitivity, indicating that the metabolic and prolactin-lowering effects of metformin are related to each other, supporting the view that prolactin plays an important role in glucose homeostasis [15,16,17,18,19,20]. More importantly, concomitant autoimmune thyroiditis weakened metformin action on glucose homeostasis, which is supported by inverse correlations between the impact on HOMA-IR and hsCRP concentrations. Though our study was not aimed at investigating molecular mechanisms of metformin action, the obtained results may suggest that relatively small changes in plasma glucose, glycated hemoglobin, and HOMA-IR resulted from markedly elevated post-treatment prolactin levels in this population and/or from interaction between proinflammatory markers and metformin at the level of the central nervous system and/or GLUT-4, the main insulin-responsive glucose transporter, which is a key regulator of systemic glucose homeostasis [25,26,47].
The most likely explanation for a mitigatory impact of Hashimoto thyroiditis on the prolactin-lowering effect of metformin is interaction at the level of the pituitary adenosine 5′-monophosphate-activated protein kinase (AMPK) pathway. Some findings support this explanation. First, activation of AMPK is one of the main mechanisms of metformin action [48]. Second, anterior pituitary cells are characterized by an abundant expression of this enzyme [49]. Third, pituitary AMPK was found to mediate the gonadotropin-lowering effects of metformin [49], and it may mediate other pituitary effects of this drug. Lastly, hsCRP and proinflammatory cytokines, found to be overproduced in Hashimoto thyroiditis [28], exert an inhibitory effect on the activity of the AMPK pathway [50,51]. Thus, it is likely that the stimulatory effect observed in men without thyroid autoimmunity is counterbalanced by the opposite effect of the proinflammatory state. This interaction may be particularly relevant in middle-age or elderly men because low testosterone production, characterizing men in these age groups, is associated with the low activity of AMPK [52]. The alternative explanation for our findings is the opposite impact of metformin and mediators of the proinflammatory state on the activity of tuberoinfundibular dopaminergic neurons, playing a fundamental role in the regulation of prolactin secretion [53]. In line with this explanation, metformin was found to increase the central dopaminergic tone [54], where proinflammatory factors inhibited the tuberoinfundibular dopaminergic system [55]. Interestingly, increased activity of both AMPK and tuberoinfundibular dopaminergic neurons is associated with increased insulin sensitivity [56,57] and may explain correlations between the impact of metformin on prolactin and HOMA-IR.
Some other conclusions can be drawn on the basis of the obtained results. First, autoimmune thyroid disease attenuates the metabolic effects of metformin in subjects without hypothyroidism. Thus, men with Hashimoto thyroiditis and either diabetes or at high diabetes risk may gain fewer benefits from metformin treatment than their peers without thyroid disease. This finding is worth underlying because euthyroid Hashimoto thyroiditis may be complicated by insulin resistance and may predispose to type-2 diabetes and prediabetes [58]. Second, in the current study, metformin was administered at a high dose (3 g daily). In our previous ones, metformin decreased prolactin levels only if the daily dose ranged from 2.55 to 3 g [8,12]. Thus, only high-dose metformin should be recommended to reduce prolactin levels in subjects with prolactin excess. However, high doses of this agent are well tolerated even in the case of prediabetes. Finally, positive correlations between changes in total and monomeric prolactin and their baseline concentrations, as well as no statistically significant changes in the concentrations of the remaining hormones, the baseline levels of which were within the reference range, suggest that metformin does not lead to hypoprolactinemia and other pituitary hormone deficiencies. This conclusion is clinically relevant because dopaminergic agents may cause prolactin deficiency, which, at least in premenopausal women, is associated with the unfavorable metabolic profile [59].
Our study provides some therapeutic implications. First, it seems justified to assess thyroid antibodies in all men requiring antipsychotic therapy. Finding autoimmune thyroiditis should be an argument against treatment with first-generation antipsychotics, amisulpride, risperidone, and paliperidone, particularly predisposing to hyperprolactinemia [60]. Second, measurement of thyroid antibodies may be considered in all insulin-resistant men poorly responding to metformin therapy, if the reason for this resistance is unknown. Third, metformin may be considered as a treatment option for antipsychotic-induced hyperprolactinemia in men without thyroid disease if other options are not available, effective, or tolerated. However, its administration should not be recommended for patients with concomitant thyroid autoimmunity. Fourth, the treatment of patients with both prolactin excess and thyroiditis may be very difficult because the prolactin-lowering effects of cabergoline in this group are weak [61]. Last, from a pathophysiological point of view, men with diabetes or prediabetes may benefit from concomitant treatment with metformin and agents reducing thyroid antibody titers, such as vitamin D, selenomethionine, and myo-inositol [62]. Certainly, it cannot be excluded that other insulin-sensitizing agents, such as dipetidyl peptidase-4 inhibitors, glucagon-like peptide-1 agonists, and thiazolidinediones, administered in monotherapy or in combination with metformin, are superior to metformin alone in patients with autoimmune thyroiditis.
The strength of our study was a homogenous population of patients, resulting from strict inclusion and exclusion criteria. Unfortunately, this causes a situation where we can only speculate about metformin action in other groups of patients, particularly individuals with severe hyperprolactinemia or hypothyroidism. For ethical reasons, we did not include men with prolactin levels above 80 ng/mL. Severe hyperprolactinemia must always be specifically addressed, even when there is no sexual dysfunction (reduced libido and/or importance) because of the medium-/long-term risk of osteoporosis and cardiovascular issues [63]. Such patients require specific treatment, including the discontinuation or decreasing the dose of the antipsychotic drug, changing the antipsychotic drug, the addition of aripiprazole, the addition of dopamine agonists, and/or symptomatic treatment) [60]. The obtained correlations (positive between metformin action on plasma prolactin and baseline prolactin levels and negative between the impact on plasma prolactin and thyroid antibody titers) suggest, however, that metformin may reduce prolactin levels also in patients with severe hyperprolactinemia, but that this effect is probably also attenuated by coexisting autoimmune thyroiditis. Moreover, we excluded not only levothyroxine-naive patients with overt or subclinical hypothyroidism but also hypothyroid individuals in whom euthyroidism was restored by levothyroxine substitution. This enabled us to eliminate possible pharmacokinetic and pharmacodynamic interactions between metformin and exogenous levothyroxine. The results of our recent study [64] indicate that metformin reduces TSH in patients with autoimmune thyroiditis-induced hypothyroidism. However, considering that the impact of this agent on TSH in hypothyroid patients was moderate, even if metformin reduces plasma prolactin in hypothyroid men with autoimmune thyroiditis and antipsychotics-induced hyperprolactinemia, this effect is probably weak and secondary to the improvement in the hypothalamic–pituitary–thyroid axis activity but not associated with a direct effect on lactotrophic cells and/or the tuberoinfundibular dopaminergic pathway.
There are several other study limitations that should be noted. Despite being adequately powered for the primary outcome, the small sample size limits the generalizability of the results. Owing to the study design, the results might have been potentially affected by selection and confounding bias. Extrapolating previous data [65,66], it seems that the study population was characterized by sufficient iodine and insufficient selenium intake. It cannot completely exclude some differences in the impact of autoimmune thyroiditis in men with inadequate iodine and/or adequate selenium intake. Strict inclusion and exclusion criteria do not allow us to conclude whether other autoimmune disorders (including Graves’ disease) modulate metformin action on antipsychotic-induced hyperprolactinemia, which justifies further studies. Precautions during study design and data analysis limited, but did not completely eliminate, the regression toward the mean [67]. Lastly, because gel-filtration chromatography is time-consuming and expensive, the macroprolactin content was measured using a less accurate polyethylene glycol precipitation method [37].
In conclusion, chronic treatment with metformin decreases elevated prolactin levels in middle-aged and elderly men receiving antipsychotic therapy. The inhibitory effect of this drug on lactotrope secretory function is not observed if hyperprolactinemia is accompanied by Hashimoto thyroiditis. This is paralleled by weaker metabolic effects in men with thyroiditis than in men without thyroid pathology. Thus, men with thyroid autoimmunity may benefit to a lesser degree from metformin treatment and may require specific therapy to lower titers of thyroid antibodies. These relationships seem similar to those in women, which suggests that the impact of autoimmune thyroiditis on metformin action is sex independent. Study limitations and the lack of other studies justify conducting a larger trial to verify the obtained results.

4. Materials and Methods

This single-center, prospective cohort study followed the principles of the Declaration of Helsinki, and its protocol was accepted by the Bioethical Committee of the Medical University of Silesia (KNW/0022/KB/207/17; 17 October 2107). All participants gave written informed consent after receiving oral and written information about the study from the investigators. Due to its character, the study did not require registration at a clinical trial registry.

4.1. Study Population

The participants of the study were recruited among middle-aged or elderly men (50–75 years old) with antipsychotic-induced hyperprolactinemia who, because of recently diagnosed type-2 diabetes or prediabetes, required metformin treatment. We included only patients with the total prolactin concentration in the range between 30 and 80 ng/mL on two different occasions and with a difference between both measurements not exceeding 10%. The widely accepted American Diabetes Association criteria were used to diagnose type-2 diabetes (fasting glucose greater than or equal to 126 mg/dL or 2 h post-challenge glucose equal to 200 mg/dL or higher) or prediabetes (fasting glucose between 100 and 125 mg/dL and/or 2 h post-challenge glucose between 140–199 mg/dL). The participants were chosen only among individuals complying with lifestyle recommendations for at least 12 weeks. The participants were allocated into one of two groups, each consisting of 24 men. The number of included patients was based on the sample-size analysis showing that 22 patients per group would be sufficient to provide significant data (25% difference in total prolactin) for 80% power with 95% confidence. Recruitment of two additional patients in each group aimed to compensate for possible dropouts. Individuals recruited to group A had to fulfill the following criteria of euthyroid Hashimoto thyroiditis: (a) titers of thyroid peroxidase antibodies (TPOAb) exceeding 100 U/mL; (b) a hypoechoic, diffusely heterogeneous echotexture with hypoechoic micronodules and/or surrounding echogenic septation on the ultrasound image; (c) plasma TSH concentration ranging from 0.4 to 4.5 mU/L; (d) free thyroxine concentration in the range between 10.2 and 21.4 pmol/L and (e) free triiodothyronine concentration in the range between 2.2 and 6.7 pmol/L. In turn, patients recruited to group B, serving as a control group, were characterized by (a) normal levels of TSH and free thyroid hormones, (b) non-elevated thyroid antibody titers, and (c) no changes in the sonographic picture of the thyroid gland. The control patients were selected from a group of 60 men who met the inclusion and exclusion criteria in order to obtain two populations similar in terms of age, body mass index (BMI), homeostatic model assessment of insulin-resistance ratio (HOMA-IR), and total prolactin concentrations. Similar proportions of men were enrolled in May or June (25 patients: group A: 13 men and group B: 12 men), and in November or December (23 patients: group A: 11 men and group B: 12 men).
The potential participants were excluded if they had a prolactin excess of another origin, macroprolactinemia, positive antibodies against thyrotropin receptor, other autoimmune or endocrine diseases, cardiovascular disorders (except for grade-1 hypertension), an estimated glomerular filtration rate less than 60 mL/min/1.73 m2, liver failure, malabsorption syndromes, oncological disorders, any other serious disorders, received other medicines (except for antipsychotic drugs), or were poorly compliant.

4.2. Study Design

The flow of patients through the study is depicted in Figure 1. The initial dosing for metformin was 500 mg by mouth twice daily. Daily dosing was then increased in 500 mg increments weekly to a target dose of 3 g (1 g three times a day). Throughout the study, antipsychotic dosing remained unchanged, and other treatments were not allowed. Non-pharmacological interventions (diet and physical activity) from before the study began were continued. Adherence to pharmacotherapy was assessed every two months by asking the patient and counting tablets.

4.3. Laboratory Assays

Blood samples for laboratory analysis were collected between 7.00 and 8.30 a.m. in a quiet and air-conditioned room (constant temperature of 23–24 °C). All assays were performed in duplicate on the first study day (before the first metformin dose) and 6 months later. Plasma levels of glucose, creatinine, and whole-blood content of glycated hemoglobin were measured using the multi-analyzer COBAS Integra 400 Plus (Roche Diagnostics, Basel, Switzerland). Titers of thyroglobulin antibodies (TgAb) and TPOAb and plasma concentrations of prolactin, insulin, thyrotropin, free thyroxine, free triiodothyronine FSH and LH were assessed using acridinium ester technology (ADVIA Centaur XP Immunoassay System, Siemens Healthcare Diagnostics, Munich, Germany). Circulating levels of adrenocorticotropic hormone (ACTH), insulin-like growth factor-1 (IGF-1), and high-sensitivity C-reactive protein (hsCRP) were measured by solid-phase enzyme-labeled chemiluminescent immunometric assays (Immulite, Siemens, Munich, Germany). Total prolactin was measured before, whereas monomeric prolactin was measured after polyethylene glycol precipitation [38]. Macroprolactin was calculated by subtracting monomeric prolactin from the total prolactin. Concentrations of adrenocorticotropic hormone (ACTH) and insulin-like growth factor-1 (IGF-1) were measured by solid-phase enzyme-labeled chemiluminescent immunometric assays (Immulite, Siemens, Munich, Germany). HOMA-IR was obtained by dividing the product of plasma glucose (in mg/dL) and insulin (in mIU/L) by 405. The estimated glomerular filtration rate was calculated as follows: 175 × [plasma creatinine (µmol/L) × 0.0113]−1.154 × age (years)0.203 (the Modification Diet in the Renal Disease Study equation).

4.4. Statistical Analysis

Prior to data analysis, all variables were subjected to log transformation to meet the criteria of normality and homogeneity. The significance of differences between means was determined by Student’s t-tests for independent samples (inter-group comparisons) or paired Student’s t-tests (intra-group comparisons). The χ2 test was used to compare dichotomous variables. Between-variable correlations were assessed using Pearson’s correlation coefficients (r). Values of p below 0.05 indicated a significant difference.

Author Contributions

R.K.: Conceptualization, Methodology, Investigation, Data curation, Writing—original draft, Writing—review and editing; M.B.: Methodology, Investigation; W.S.: Methodology, Data curation; B.O.: Resources, Writing—review and editing, Supervision. All authors have read and agreed to the published version of the manuscript.

Funding

This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Institutional Review Board Statement

The study followed the principles of the Declaration of Helsinki, and its protocol was accepted by the Bioethical Committee of the Medical University of Silesia (KNW /0022/KB/207/17; 17 October 2107).

Informed Consent Statement

All participants gave written informed consent after receiving oral and written information about the study from the investigators.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

ACTH—adrenocorticotropic hormone; AMPK—adenosine 5′-monophosphate-activated protein kinase; FSH—follicle-stimulating hormone; HOMA-IR—homeostatic model assessment of insulin-resistance ratio; hsCRP—high-sensitivity C-reactive protein; IGF-1—insulin-like growth factor-1; LH—luteinizing hormone; TgAb—thyroglobulin antibodies; TPOAb—thyroid peroxidase antibodies; TSH—thyroid-stimulating hormone.

References

  1. Ueno, M. Molecular anatomy of the brain endothelial barrier: An overview of the distributional features. Curr. Med. Chem. 2007, 14, 1199–1206. [Google Scholar] [CrossRef] [PubMed]
  2. Wróbel, M.P.; Marek, B.; Kajdaniuk, D.; Rokicka, D.; Szymborska-Kajanek, A.; Strojek, K. Metformin—A new old drug. Endokrynol. Pol. 2017, 68, 482–496. [Google Scholar] [CrossRef]
  3. Labuzek, K.; Suchy, D.; Gabryel, B.; Bielecka, A.; Liber, S.; Okopień, B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol. Rep. 2010, 62, 956–965. [Google Scholar] [CrossRef] [PubMed]
  4. Cappelli, C.; Rotondi, M.; Pirola, I.; Agosti, B.; Gandossi, E.; Valentini, U.; De Martino, E.; Cimino, A.; Chiovato, L.; Agabiti-Rosei, E.; et al. TSH-lowering effect of metformin in type 2 diabetic patients: Differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care 2009, 32, 1589–1590. [Google Scholar] [CrossRef] [PubMed]
  5. Meng, X.; Xu, S.; Chen, G.; Derwahl, M.; Liu, C. Metformin and thyroid disease. J. Endocrinol. 2017, 233, R43–R51. [Google Scholar] [CrossRef] [PubMed]
  6. Krysiak, R.; Szkróbka, W.; Okopień, B. The effect of metformin on serum gonadotropin levels in postmenopausal women with diabetes and prediabetes: A pilot study. Exp. Clin. Endocrinol. Diabetes 2018, 126, 645–650. [Google Scholar] [CrossRef]
  7. Velija-Ašimi, Z. Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment. Bosn. J. Basic Med. Sci. 2013, 13, 180–185. [Google Scholar] [CrossRef]
  8. Krysiak, R.; Okrzesik, J.; Okopień, B. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: A pilot study. Endocrine 2015, 49, 242–249. [Google Scholar] [CrossRef]
  9. Wu, R.R.; Jin, H.; Gao, K.; Twamley, E.W.; Ou, J.J.; Shao, P.; Wang, J.; Guo, X.F.; Davis, J.M.; Chan, P.K.; et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with worst-episode schizophrenia: A double-blind, randomized, placebo-controlled study. Am. J. Psychiatry 2012, 169, 813–821. [Google Scholar] [CrossRef]
  10. Zheng, W.; Yang, X.H.; Cai, D.B.; Ungvari, G.S.; Ng, C.H.; Wang, N.; Ning, Y.P.; Xiang, Y.T. Adjunctive metformin for antipsychotic related hyperprolactinemia: A meta-analysis of randomized controlled trials. J. Psychopharmacol. 2017, 31, 625–631. [Google Scholar] [CrossRef]
  11. Bo, Q.J.; Wang, Z.M.; Li, X.B.; Ma, X.; Wang, C.Y.; de Leon, J. Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review. Psychiatry Res. 2016, 237, 257–263. [Google Scholar] [CrossRef] [PubMed]
  12. Krysiak, R.; Kowalcze, K.; Szkróbka, W.; Okopień, B. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. Eur. J. Intern. Med. 2016, 30, 94–98. [Google Scholar] [CrossRef] [PubMed]
  13. Auriemma, R.S.; Pirchio, R.; De Alcubierre, D.; Pivonello, R.; Colao, A. Dopamine agonists: From the 1970s to today. Neuroendocrinology 2019, 109, 34–41. [Google Scholar] [CrossRef] [PubMed]
  14. Rusgis, M.M.; Alabbasi, A.Y.; Nelson, L.A. Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option. Am. J. Health Syst. Pharm. 2021, 78, 862–871. [Google Scholar] [CrossRef] [PubMed]
  15. Auriemma, R.S.; De Alcubierre, D.; Pirchio, R.; Pivonello, R.; Colao, A. The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev. Endocrinol. Metab. 2018, 13, 99–106. [Google Scholar] [CrossRef] [PubMed]
  16. Auriemma, R.S.; De Alcubierre, D.; Pirchio, R.; Pivonello, R.; Colao, A. Glucose abnormalities associated to prolactin secreting pituitary adenomas. Front. Endocrinol. 2019, 10, 327. [Google Scholar] [CrossRef] [PubMed]
  17. Andersen, M.; Glintborg, D. Metabolic syndrome in hyperprolactinemia. Front. Horm. Res. 2018, 49, 29–47. [Google Scholar] [PubMed]
  18. Arslan, M.S.; Topaloglu, O.; Sahin, M.; Tutal, E.; Gungunes, A.; Cakir, E.; Ozturk, I.U.; Karbek, B.; Ucan, B.; Ginis, Z.; et al. Preclinical atherosclerosis in patients with prolactinoma. Endocr. Pract. 2014, 20, 447–451. [Google Scholar] [CrossRef]
  19. Gierach, M.; Bruska-Sikorska, M.; Rojek, M.; Junik, R. Hyperprolactinemia and insulin resistance. Endokrynol. Pol. 2022, 73, 959–967. [Google Scholar] [CrossRef]
  20. Yavuz, D.; Deyneli, O.; Akpinar, I.; Yildiz, E.; Gözü, H.; Sezgin, O.; Haklar, G.; Akalin, S. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur. J. Endocrinol. 2003, 149, 187–193. [Google Scholar] [CrossRef]
  21. Krysiak, R.; Szkróbka, W.; Okopień, B. Sex-dependent effect of metformin on serum prolactin levels in hyperprolactinemic patients with type 2 diabetes: A pilot study. Exp. Clin. Endocrinol. Diabetes 2018, 126, 342–348. [Google Scholar] [CrossRef]
  22. Krysiak, R.; Szkróbka, W.; Okopień, B. Endogenous testosterone determines metformin action on prolactin levels in hyperprolactinaemic men: A pilot study. Basic Clin. Pharmacol. Toxicol. 2020, 126, 110–115. [Google Scholar] [CrossRef]
  23. Cunningham, G.R. Testosterone and metabolic syndrome. Asian J. Androl. 2015, 17, 192–196. [Google Scholar] [CrossRef]
  24. Louters, M.; Pearlman, M.; Solsrud, E.; Pearlman, A. Functional hypogonadism among patients with obesity, diabetes, and metabolic syndrome. Int. J. Impot. Res. 2022, 34, 714–720. [Google Scholar] [CrossRef]
  25. Krysiak, R.; Basiak, M.; Machnik, G.; Okopień, B. Impaired gonadotropin-lowering effects of metformin in postmenopausal women with autoimmune thyroiditis: A pilot study. Pharmaceuticals 2023, 16, 922. [Google Scholar] [CrossRef]
  26. Krysiak, R.; Kowalcze, K.; Madej, A.; Okopień, B. The effect of metformin on plasma prolactin levels in young women with autoimmune thyroiditis. J. Clin. Med. 2023, 12, 3769. [Google Scholar] [CrossRef]
  27. Gessl, A.; Lemmens-Gruber, R.; Kautzky-Willer, A. Thyroid disorders. Handb. Exp. Pharmacol. 2012, 214, 361–386. [Google Scholar]
  28. Merrill, S.J.; Minucci, S.B. Thyroid autoimmunity: An interplay of factors. Vitam. Horm. 2018, 106, 129–145. [Google Scholar]
  29. Ragusa, F.; Fallahi, P.; Elia, G.; Gonnella, D.; Paparo, S.R.; Giusti, C.; Churilov, L.P.; Ferrari, S.M.; Antonelli, A. Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy. Best Pract. Res. Clin. Endocrinol. Metab. 2019, 34, 101367. [Google Scholar] [CrossRef]
  30. Wortsman, J.; Rosner, W.; Dufau, M.L. Abnormal testicular function in men with primary hypothyroidism. Am. J. Med. 1987, 82, 207–212. [Google Scholar] [CrossRef] [PubMed]
  31. Chen, Y.; Chen, Y.; Xia, F.; Wang, N.; Chen, C.; Nie, X.; Li, Q.; Han, B.; Zhai, H.; Jiang, B.; et al. A higher ratio of estradiol to testosterone is associated with autoimmune thyroid disease in males. Thyroid 2017, 27, 960–966. [Google Scholar] [CrossRef] [PubMed]
  32. Doukas, C.; Saltiki, K.; Mantzou, A.; Cimponeriu, A.; Terzidis, K.; Sarika, L.; Mavrikakis, M.; Sfikakis, P.; Alevizaki, M. Hormonal parameters and sex hormone receptor gene polymorphisms in men with autoimmune diseases. Rheumatol. Int. 2013, 34, 575–582. [Google Scholar] [CrossRef] [PubMed]
  33. Casto, C.; Pepe, G.; Li Pomi, A.; Corica, D.; Aversa, T.; Wasniewska, M. Hashimoto thyroiditis and Graves’ disease in genetic syndromes in pediatric age. Genes 2021, 12, 222. [Google Scholar] [CrossRef] [PubMed]
  34. Krysiak, R.; Kowalcze, K.; Okopień, B. The effect of testosterone on thyroid autoimmunity in euthyroid men with Hashimoto thyroiditis and low testosterone levels. J. Clin. Pharm. Ther. 2019, 44, 742–749. [Google Scholar] [CrossRef] [PubMed]
  35. Samperi, I.; Lithgow, K.; Karavitaki, N. Hyperprolactinaemia. J. Clin. Med. 2019, 8, 2203. [Google Scholar] [CrossRef]
  36. Borba, V.V.; Zandman-Goddard, G.; Shoenfeld, Y. Prolactin and autoimmunity. Front. Immunol. 2018, 9, 73. [Google Scholar] [CrossRef]
  37. Fahie-Wilson, M.N.; John, R.; Ellis, A.R. Macroprolactin; high molecular mass forms of circulating prolactin. Ann. Clin. Biochem. 2005, 42 Pt 3, 175–192. [Google Scholar] [CrossRef] [PubMed]
  38. Krysiak, R.; Szkróbka, W.; Okopień, B. A neutral effect of metformin treatment on macroprolactin content in women with macroprolactinemia. Exp. Clin. Endocrinol. Diabetes 2016, 125, 223–228. [Google Scholar] [CrossRef] [PubMed]
  39. Cocks Eschler, D.; Javanmard, P.; Cox, K.; Geer, E.B. Prolactinoma through the female life cycle. Endocrine 2018, 59, 16–29. [Google Scholar] [CrossRef]
  40. Bottai, T.; Quintin, P.; Perrin, E. Antipsychotics and the risk of diabetes: A general data review. Eur. Psychiatry 2005, 20 (Suppl. S4), S349–S357. [Google Scholar] [CrossRef]
  41. ThirumalaI, A.; Anawalt, B.D. Epidemiology of male hypogonadism. Endocrinol. Metab. Clin. N. Am. 2022, 51, 1–27. [Google Scholar] [CrossRef] [PubMed]
  42. Caturegli, P.; De Remigis, A.; Rose, N.R. Hashimoto thyroiditis: Clinical and diagnostic criteria. Autoimmun. Rev. 2014, 13, 391–397. [Google Scholar] [CrossRef] [PubMed]
  43. Orgiazzi, J. Thyroid autoimmunity. Presse Med. 2012, 41, e611–e625. [Google Scholar] [CrossRef] [PubMed]
  44. Vilar, L.; Vilar, C.F.; Lyra, R.; Freitas, M.D. Pitfalls in the diagnostic evaluation of hyperprolactinemia. Neuroendocrinology 2019, 109, 7–19. [Google Scholar] [CrossRef] [PubMed]
  45. Sharif, K.; Tiosano, S.; Watad, A.; Comaneshter, D.; Cohen, A.D.; Shoenfeld, Y.; Amital, H. The link between schizophrenia and hypothyroidism: A population-based study. Immunol. Res. 2018, 66, 663–667. [Google Scholar] [CrossRef]
  46. Jia, X.; Zhai, T.; Zhang, J.A. Metformin reduces autoimmune antibody levels in patients with Hashimoto thyroiditis: A systematic review and meta-analysis. Autoimmunity 2020, 53, 353–361. [Google Scholar] [CrossRef] [PubMed]
  47. Yaribeygi, H.; Farrokhi, F.R.; Butler, A.E.; Sahebkar, A. Insulin resistance: Review of the underlying molecular mechanisms. J. Cell. Physiol. 2019, 234, 81527–88161. [Google Scholar] [CrossRef] [PubMed]
  48. Rena, G.; Hardie, D.G.; Pearson, E.R. The mechanisms of action of metformin. Diabetologia 2017, 60, 1577–1585. [Google Scholar] [CrossRef] [PubMed]
  49. Tosca, L.; Froment, P.; Rame, C.; McNeilly, J.R.; McNeilly, A.S.; Maillard, V.; Dupont, J. Metformin decreases GnRH- and activin-induced gonadotropin secretion in rat pituitary cells: Potential involvement of adenosine 5′ monophosphate-activated protein kinase (PRKA). Biol. Reprod. 2011, 84, 351–362. [Google Scholar] [CrossRef] [PubMed]
  50. O’Neill, L.A.; Hardie, D.G. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013, 493, 346–355. [Google Scholar] [CrossRef]
  51. Jeon, S.M. Regulation and function of AMPK in physiology and diseases. Exp. Mol. Med. 2016, 48, e245. [Google Scholar] [CrossRef] [PubMed]
  52. Ghanim, H.; Dhindsa, S.; Batra, M.; Green, K.; Abuaysheh, S.; Kuhadiya, N.D.; Makdissi, A.; Chaudhuri, A.; Sandhu, S.; Dandona, P. Testosterone increases the expression and phosphorylation of AMP kinase α in men with hypogonadism and type 2 diabetes. J. Clin. Endocrinol. Metab. 2020, 105, 1169–1175. [Google Scholar] [CrossRef] [PubMed]
  53. Grattan, D.R. 60 years of neuroendocrinology: The hypothalamo-prolactin axis. J. Endocrinol. 2015, 226, T101–T122. [Google Scholar] [CrossRef] [PubMed]
  54. Ortega-González, C.; Cardoza, L.; Coutiño, B.; Hidalgo, R.; Arteaga-Troncoso, G.; Parra, A. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J. Endocrinol. 2005, 184, 232–239. [Google Scholar] [CrossRef] [PubMed]
  55. González, M.C.; Abreu, P.; Barroso-Chinea, P.; Cruz-Muros, I.; González-Hernández, T. Effect of intracerebroventricular injection of lipopolysaccharide on the tuberoinfundibular dopaminergic system of the rat. Neuroscience 2004, 127, 251–259. [Google Scholar] [CrossRef]
  56. Smith, B.K.; Steinberg, G.R. AMP-activated protein kinase, fatty acid metabolism, and insulin sensitivity. Curr. Opin. Clin. Nutr. Metab. Care 2017, 20, 248–253. [Google Scholar] [CrossRef] [PubMed]
  57. Chien, H.Y.; Chen, S.M.; Li, W.C. Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions. Front. Clin. Diabetes Healthc. 2023, 4, 935872. [Google Scholar] [CrossRef]
  58. Blaslov, K.; Gajski, D.; Vucelić, V.; Gaćina, P.; Mirošević, G.; Marinković, J.; Vrkljan, M.; Rotim, K. The association of subclinical insulin resistance with thyroid autoimmunity in euthyroid individuals. Acta Clin. Croat. 2020, 59, 696–702. [Google Scholar] [CrossRef] [PubMed]
  59. Krysiak, R.; Kowalcze, K.; Okopień, B. Cardiometabolic profile of young women with hypoprolactinemia. Endocrine 2022, 78, 135–141. [Google Scholar] [CrossRef] [PubMed]
  60. Montejo, Á.L.; Arango, C.; Bernardo, M.; Carrasco, J.L.; Crespo-Facorro, B.; Del Pino-Montes, J.; García-Escudero, M.A.; García-Rizo, C.; González-Pinto, A.; Hernández, A.I.; et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front. Neuroendocrinol. 2017, 45, 25–34. [Google Scholar] [CrossRef]
  61. Krysiak, R.; Kowalcze, K.; Okopień, B. Autoimmune thyroiditis attenuates cardiometabolic effects of cabergoline in young women with hyperprolactinemia. J. Clin. Pharmacol. 2023, 63, 886–894. [Google Scholar] [CrossRef] [PubMed]
  62. Krysiak, R.; Kowalcze, K.; Szkróbka, W.; Okopień, B. Sexual function and depressive symptoms in young women with euthyroid Hashimoto thyroiditis receiving vitamin D, selenomethionine and myo-inositol: A pilot study. Nutrients 2023, 15, 2815. [Google Scholar] [CrossRef] [PubMed]
  63. Grigg, J.; Worsley, R.; Thew, C.; Gurvich, C.; Thomas, N.; Kulkarni, J. Antipsychotic-induced hyperprolactinemia: Synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology 2017, 234, 3279–3297. [Google Scholar] [CrossRef] [PubMed]
  64. Krysiak, R.; Kowalcze, K.; Okopień, B. Impact of metformin on hypothalamic-pituitary-thyroid axis activity in women with autoimmune and non-autoimmune subclinical hypothyroidism: A pilot study. Pharmacol. Rep. 2024, 76, 195–206. [Google Scholar] [CrossRef] [PubMed]
  65. Trofimiuk-Müldner, M.; Konopka, J.; Sokołowski, G.; Dubiel, A.; Kieć-Klimczak, M.; Kluczyński, Ł.; Motyka, M.; Rzepka, E.; Walczyk, J.; Sokołowska, M.; et al. Current iodine nutrition status in Poland (2017): Is the Polish model of obligatory iodine prophylaxis able to eliminate iodine deficiency in the population? Public Health Nutr. 2020, 23, 2467–2477. [Google Scholar] [CrossRef] [PubMed]
  66. Kłapcińska, B.; Poprzecki, S.; Danch, A.; Sobczak, A.; Kempa, K. Selenium levels in blood of Upper Silesian population: Evidence of suboptimal selenium status in a significant percentage of the population. Biol. Trace Elem. Res. 2005, 108, 1–15. [Google Scholar] [CrossRef]
  67. Streiner, D.L. Regression toward the mean: Its etiology, diagnosis, and treatment. Can. J. Psychiatry 2001, 46, 72–76. [Google Scholar] [CrossRef]
Pharmaceuticals 17 00976 g001
Figure 1. Flow the patients through the study.
Figure 1. Flow the patients through the study.
Pharmaceuticals 17 00976 g001
Table 1. Baseline characteristics of both study groups.
Table 1. Baseline characteristics of both study groups.
VariableGroup AGroup Bp-Value
Number (n)2424-
Age (years)60 ± 862 ± 90.4200
Type-2 diabetes (%)/prediabetes (%)50/5054/460.8342
Smokers (%)/Number of cigarettes a day (n)/Duration of smoking (years)42/11 ± 5/32 ± 1046/10 ± 6/34 ± 110.7523
BMI (kg/m2)24.9 ± 4.324.5 ± 4.80.7624
Systolic blood pressure (mmHg)130 ± 15128 ± 140.6352
Diastolic blood pressure (mmHg)85 ± 584 ± 50.4918
Group A: males with iatrogenic prolactin excess and euthyroid Hashimoto disease. Group B: males with iatrogenic prolactin excess but without thyroid disease. Except for the percentages of smokers, patients with type-2 diabetes, and individuals with prediabetes, the data have been shown as the mean ± standard deviation. Abbreviation: BMI—body mass index.
Table 2. The impact of metformin treatment on the assessed variables.
Table 2. The impact of metformin treatment on the assessed variables.
VariableGroup AGroup Bp-Value *
Glucose (mg/dL) [70–99]
Baseline121 ± 11123 ± 120.5502
Follow-up112 ± 10105 ± 100.0193
p-value ** 0.0048<0.0001-
HOMA1-IR [<2.0]
Baseline4.2 ± 1.34.0 ± 1.20.5824
Follow-up3.2 ± 1.02.1 ± 0.80.0001
p-value **0.0045<0.0001-
Glycated hemoglobin [4.0–5.6]
Baseline6.7 ± 0.56.8 ± 0.60.5346
Follow-up6.3 ± 0.55.9 ± 0.40.0037
p-value **0.0080<0.0001-
Total prolactin (ng/mL) [5–17]
Baseline55.2 ± 12.356.8 ± 13.80.6735
Follow-up52.7 ± 13.444.8 ± 11.80.0354
p-value **0.57020.0022-
Monomeric prolactin (ng/mL) [3–15]
Baseline50.4 ± 11.252.5 ± 12.90.5500
Follow-up48.6 ± 10.640.9 ± 11.60.0216
p-value **0.59180.0020-
Macroprolactin (ng/mL) [2–12]
Baseline4.8 ± 3.14.3 ± 2.90.5667
Follow-up4.1 ± 3.53.9 ± 2.50.8208
p-value **0.46700.6112-
TPOAb (IU/mL) [<35]
Baseline840 ± 30513 ± 12<0.0001
Follow-up668 ± 28511 ± 14<0.0001
p-value **0.09780.5978-
TgAb (IU/mL) [<35]
Baseline828 ± 32017 ± 12<0.0001
Follow-up685 ± 27616 ± 18<0.0001
p-value **0.10420.8219-
TSH (mIU/L) [0.4–4.5]
Baseline3.2 ± 1.33.0 ± 1.40.6105
Follow-up2.8 ± 1.22.3 ± 1.20.1557
p-value **0.27380.0693-
Free thyroxine (pmol/L) [10.2–21.4]
Baseline14.8 ± 2.415.2 ± 2.60.5824
Follow-up15.1 ± 2.715.6 ± 2.90.5395
p-value **0.68600.6174-
Free triiodothyronine (pmol/L) [2.2–6.7]
Baseline3.6 ± 0.83.5 ± 0.90.6860
Follow-up3.7 ± 0.83.7 ± 1.01.0000
p-value **0.66700.4701-
FSH (U/L) [1.5–9.5]
Baseline3.4 ± 1.03.2 ± 1.20.5346
Follow-up3.7 ± 1.3 3.6 ± 1.40.7988
p-value **0.37490.2934-
LH (U/L) [1.5–8.5]
Baseline2.9 ± 0.83.0 ± 1.40.7626
Follow-up3.2 ± 1.03.6 ± 1.10.1940
p-value **0.25710.1056-
Testosterone (ng/mL) [3.5–17.0]
Baseline4.4 ± 1.04.2 ± 1.30.5532
Follow-up4.7 ± 1.24.9 ± 1.50.6125
p-value **0.35170.908-
ACTH (pg/mL) [15–70]
Baseline29 ± 1434 ± 180.2883
Follow-up35 ± 1538 ± 160.5061
p-value **0.15870.4200-
IGF-1 (ng/mL) [50–180]
Baseline102 ± 4897 ± 400.6968
Follow-up114 ± 50118 ± 600.8030
p-value **0.40070.1604-
hsCRP (mg/L) [<1.5]
Baseline2.8 ± 1.02.2 ± 0.80.0263
Follow-up2.6 ± 0.81.5 ± 0.6<0.0001
p-value **0.44810.0013-
Estimated glomerular filtration rate (mL/min/1.73 m2) [<60]
Baseline89 ± 1391 ± 150.6239
After 6 months92 ± 1492 ± 161.0000
p-value **0.44570.8242-
* Group A vs. Group B, ** Follow-up vs. baseline. Group A: males with iatrogenic prolactin excess and euthyroid Hashimoto disease. Group B: males with iatrogenic prolactin excess but without thyroid disease. Except for the percentage of smokers, the data have been shown as the mean ± standard deviation. Reference values are shown in square brackets. Abbreviations: ACTH—adrenocorticotropic hormone; FSH—follicle-stimulating hormone; HOMA-IR—the homeostatic model assessment of insulin-resistance ratio; hsCRP—high-sensitivity C-reactive protein; IGF-1—insulin growth factor-1; LH—luteinizing hormone; TgAb—thyroglobulin antibodies; TPOAb—thyroid peroxidase antibodies; TSH—thyroid-stimulating hormone.
Table 3. Percentage changes from baseline in the investigated variables during metformin treatment.
Table 3. Percentage changes from baseline in the investigated variables during metformin treatment.
VariableGroup AGroup Bp-Value
Δ Glucose −7 ± 3−15 ± 6<0.0001
Δ HOMA1-IR −24 ± 20−48 ± 230.0004
Δ Glycated hemoglobin−6 ± 5−13 ± 5<0.0001
Δ Total prolactin−5 ± 8−21 ± 8<0.0001
Δ Monomeric prolactin−3 ± 7−22 ± 10<0.0001
Δ Macroprolactin−15 ± 18−9 ± 200.2803
Δ TPOAb −20 ± 18−15 ± 240.4184
Δ TgAb −17 ± 23−6 ± 280.1438
Δ TSH −13 ± 14−23 ± 220.0667
Δ Free thyroxine 2 ± 63 ± 70.5988
Δ Free triiodothyronine 3 ± 106 ± 140.3974
Δ FSH9 ± 1013 ± 120.2160
Δ LH 10 ± 1220 ± 230.0653
Δ Testosterone 7 ± 1317 ± 200.0457
Δ ACTH 21 ± 2012 ± 180.1081
Δ IGF-1 12 ± 2522 ± 200.1328
Δ hsCRP−7 ± 14−32 ± 20<0.0001
Δ Estimated glomerular filtration rate3 ± 71 ± 60.2934
Group A: males with iatrogenic prolactin excess and euthyroid Hashimoto disease. Group B: males with iatrogenic prolactin excess but without thyroid disease. Except for the percentage of smokers, the data have been shown as the mean ± standard deviation. Abbreviations: ACTH—adrenocorticotropic hormone; FSH—follicle-stimulating hormone; HOMA-IR—the homeostatic model assessment of insulin-resistance ratio; hsCRP—high-sensitivity C-reactive protein; IGF-1—insulin growth factor-1; LH—luteinizing hormone; TgAb—thyroglobulin antibodies; TPOAb—thyroid peroxidase antibodies; TSH—thyroid-stimulating hormone.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Krysiak, R.; Basiak, M.; Szkróbka, W.; Okopień, B. Autoimmune Thyroiditis Mitigates the Effect of Metformin on Plasma Prolactin Concentration in Men with Drug-Induced Hyperprolactinemia. Pharmaceuticals 2024, 17, 976. https://doi.org/10.3390/ph17080976

AMA Style

Krysiak R, Basiak M, Szkróbka W, Okopień B. Autoimmune Thyroiditis Mitigates the Effect of Metformin on Plasma Prolactin Concentration in Men with Drug-Induced Hyperprolactinemia. Pharmaceuticals. 2024; 17(8):976. https://doi.org/10.3390/ph17080976

Chicago/Turabian Style

Krysiak, Robert, Marcin Basiak, Witold Szkróbka, and Bogusław Okopień. 2024. "Autoimmune Thyroiditis Mitigates the Effect of Metformin on Plasma Prolactin Concentration in Men with Drug-Induced Hyperprolactinemia" Pharmaceuticals 17, no. 8: 976. https://doi.org/10.3390/ph17080976

APA Style

Krysiak, R., Basiak, M., Szkróbka, W., & Okopień, B. (2024). Autoimmune Thyroiditis Mitigates the Effect of Metformin on Plasma Prolactin Concentration in Men with Drug-Induced Hyperprolactinemia. Pharmaceuticals, 17(8), 976. https://doi.org/10.3390/ph17080976

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop